{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T16:24:32Z","timestamp":1772209472202,"version":"3.50.1"},"reference-count":54,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 RR13273"],"award-info":[{"award-number":["R01 RR13273"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["AI30034"],"award-info":[{"award-number":["AI30034"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI30034"],"award-info":[{"award-number":["AI30034"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RR-00166"],"award-info":[{"award-number":["RR-00166"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Rationale\/Study design<\/jats:title>\n                    <jats:p>\n                      A major challenge in the development of HIV vaccines is finding immunogens that elicit protection against a broad range of viral strains. Immunity to a narrow range of viral strains may protect infants of HIV-infected women or partners discordant for HIV. We hypothesized that immunization to the relevant viral variants could be achieved by exposure to infectious virus during prophylaxis with antiretroviral drugs. To explore this approach in an animal model, macaques were exposed to live virus (SIV\n                      <jats:sub>mne<\/jats:sub>\n                      or HIV-2\n                      <jats:sub>287<\/jats:sub>\n                      ) during prophylaxis with parenteral tenofovir and humoral and cellular immune responses were quantified. Subsequently, experimental animals were challenged with homologous virus to evaluate protection from infection, and if infection occurred, the course of disease was compared to control animals. Experimental animals uninfected with SIV\n                      <jats:sub>mne<\/jats:sub>\n                      were challenged with heterologous HIV-2\n                      <jats:sub>287<\/jats:sub>\n                      to assess resistance to retroviral infection.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methodology\/Principal findings<\/jats:title>\n                    <jats:p>\n                      Juvenile female\n                      <jats:italic>Macaca nemestrina<\/jats:italic>\n                      (N = 8) were given ten weekly intravaginal exposures with either moderately (SIV\n                      <jats:sub>mne<\/jats:sub>\n                      ) or highly (HIV-2\n                      <jats:sub>287<\/jats:sub>\n                      ) pathogenic virus during tenofovir prophylaxis. Tenofovir protected all 8 experimental animals from infection, while all untreated control animals became infected. Specific non-neutralizing antibodies were elicited in blood and vaginal secretions of experimental animals, but no ELISPOT responses were detected. Six weeks following the cessation of tenofovir, intravaginal challenge with homologous virus infected 2\/4 (50%) of the SIV\n                      <jats:sub>mne<\/jats:sub>\n                      -immunized animals and 4\/4 (100%) of the HIV-2\n                      <jats:sub>287<\/jats:sub>\n                      -immunized animals. The two SIV\n                      <jats:sub>mne<\/jats:sub>\n                      -infected and 3 (75%) HIV-2\n                      <jats:sub>287<\/jats:sub>\n                      -infected had attenuated disease, suggesting partial protection.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions\/Significance<\/jats:title>\n                    <jats:p>\n                      Repeated exposure to SIV\n                      <jats:sub>mne<\/jats:sub>\n                      or HIV-2\n                      <jats:sub>287<\/jats:sub>\n                      , during antiretroviral prophylaxis that blocked infection, induced binding antibodies in the blood and mucosa, but not neutralizing antibodies or specific cellular immune responses. Studies to determine whether antibodies are similarly induced in breastfeeding infants and sexual partners discordant for HIV infection and receiving pre-exposure antiretroviral prophylaxis are warranted, including whether these antibodies appear to confer partial or complete protection from infection.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0240495","type":"journal-article","created":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T13:51:37Z","timestamp":1619704297000},"page":"e0240495","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunization by exposure to live virus (SIVmne\/HIV-2287) during antiretroviral drug prophylaxis may reduce risk of subsequent viral challenge"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9566-8959","authenticated-orcid":true,"given":"Lisa M.","family":"Frenkel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LaRene","family":"Kuller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid A.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Che-Chung","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaimy P.","family":"Joy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thera M.","family":"Mulvania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiu-Lok","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Montefiori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,4,29]]},"reference":[{"issue":"4","key":"pone.0240495.ref001","article-title":"Advances in HIV-1 Vaccine Development","volume":"10","author":"Y Gao","year":"2018","journal-title":"Viruses"},{"issue":"1","key":"pone.0240495.ref002","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/imr.12511","article-title":"Use of broadly neutralizing antibodies for HIV-1 prevention","volume":"275","author":"A Pegu","year":"2017","journal-title":"Immunol Rev"},{"issue":"12","key":"pone.0240495.ref003","doi-asserted-by":"crossref","first-page":"6155","DOI":"10.1128\/JVI.00093-06","article-title":"Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses","volume":"80","author":"SG Deeks","year":"2006","journal-title":"J Virol"},{"issue":"2","key":"pone.0240495.ref004","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/72309","article-title":"Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection","volume":"6","author":"TW Baba","year":"2000","journal-title":"Nat Med"},{"issue":"2","key":"pone.0240495.ref005","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/72318","article-title":"Protection of macaques against vaginal transmission of a pathogenic HIV-1\/SIV chimeric virus by passive infusion of neutralizing antibodies","volume":"6","author":"JR Mascola","year":"2000","journal-title":"Nat Med"},{"issue":"3","key":"pone.0240495.ref006","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nm833","article-title":"Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120","volume":"9","author":"RS Veazey","year":"2003","journal-title":"Nat Med"},{"issue":"2","key":"pone.0240495.ref007","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/COH.0000000000000442","article-title":"Neutralization tiers of HIV-1","volume":"13","author":"DC Montefiori","year":"2018","journal-title":"Curr Opin HIV AIDS"},{"issue":"1","key":"pone.0240495.ref008","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cell.2013.03.018","article-title":"Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization","volume":"153","author":"F Klein","year":"2013","journal-title":"Cell"},{"issue":"2","key":"pone.0240495.ref009","doi-asserted-by":"crossref","first-page":"982","DOI":"10.4049\/jimmunol.1000221","article-title":"Low-level exposure to HIV induces virus-specific T cell responses and immune activation in exposed HIV-seronegative individuals","volume":"185","author":"C Restrepo","year":"2010","journal-title":"J Immunol"},{"issue":"12","key":"pone.0240495.ref010","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1097\/00002030-200208160-00004","article-title":"HIV-specific CD8 T-cell activity in uninfected injection drug users is associated with maintenance of seronegativity","volume":"16","author":"G Makedonas","year":"2002","journal-title":"AIDS"},{"issue":"11","key":"pone.0240495.ref011","doi-asserted-by":"crossref","first-page":"5315","DOI":"10.1128\/JVI.00230-16","article-title":"Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates","volume":"90","author":"R Le Grand","year":"2016","journal-title":"J Virol"},{"issue":"5","key":"pone.0240495.ref012","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"JM Baeten","year":"2012","journal-title":"N Engl J Med"},{"issue":"9883","key":"pone.0240495.ref013","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/S0140-6736(13)61127-7","article-title":"Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"381","author":"K Choopanya","year":"2013","journal-title":"Lancet"},{"issue":"Suppl 3","key":"pone.0240495.ref014","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1086\/651479","article-title":"Antiretroviral agents used by HIV-uninfected persons for prevention: pre- and postexposure prophylaxis","volume":"50","author":"RM Grant","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"5","key":"pone.0240495.ref015","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMoa1110711","article-title":"Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana","volume":"367","author":"MC Thigpen","year":"2012","journal-title":"N Engl J Med"},{"issue":"21","key":"pone.0240495.ref016","doi-asserted-by":"crossref","first-page":"9855","DOI":"10.1128\/JVI.01482-16","article-title":"HIV-1-Neutralizing IgA Detected in Genital Secretions of Highly HIV-1-Exposed Seronegative Women on Oral Preexposure Prophylaxis","volume":"90","author":"JM Lund","year":"2016","journal-title":"J Virol"},{"issue":"4935","key":"pone.0240495.ref017","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1126\/science.2555923","article-title":"A formalin-inactivated whole SIV vaccine confers protection in macaques","volume":"246","author":"M Murphey-Corb","year":"1989","journal-title":"Science"},{"issue":"6343","key":"pone.0240495.ref018","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/353393a0","article-title":"Anti-cell antibody in macaques","volume":"353","author":"EJ Stott","year":"1991","journal-title":"Nature"},{"issue":"7","key":"pone.0240495.ref019","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1097\/QAD.0b013e3280f00fb3","article-title":"Highly efficient HIV transmission to young women in South Africa","volume":"21","author":"AE Pettifor","year":"2007","journal-title":"AIDS"},{"issue":"3\u20134","key":"pone.0240495.ref020","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1600-0684.1989.tb00225.x","article-title":"Transmission of the simian immunodeficiency virus SIVmne in macaques and baboons","volume":"18","author":"WR Morton","year":"1989","journal-title":"J Med Primatol"},{"issue":"16","key":"pone.0240495.ref021","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1089\/aid.1997.13.1375","article-title":"Early postinfection antiviral treatment reduces viral load and prevents CD4+ cell decline in HIV type 2-infected macaques","volume":"13","author":"A Watson","year":"1997","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"3","key":"pone.0240495.ref022","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1089\/088922201750063160","article-title":"Real-time TaqMan PCR as a specific and more sensitive alternative to the branched-chain DNA assay for quantitation of simian immunodeficiency virus RNA","volume":"17","author":"CM Leutenegger","year":"2001","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"3","key":"pone.0240495.ref023","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1089\/aid.1992.8.357","article-title":"Macaque CD4+ T-cell subsets: influence of activation on infection by simian immunodeficiency viruses (SIV)","volume":"8","author":"PP Firpo","year":"1992","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"4\u20135","key":"pone.0240495.ref024","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1600-0684.1999.tb00268.x","article-title":"Antigen-specific cytokine responses in vaccinated Macaca nemestrina","volume":"28","author":"T Mulvania","year":"1999","journal-title":"J Med Primatol"},{"issue":"2\u20133","key":"pone.0240495.ref025","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1600-0684.1998.tb00231.x","article-title":"Natural history of SIVmac BK28 and H824 infection in Macaca nemestrina","volume":"27","author":"T Mulvania","year":"1998","journal-title":"J Med Primatol"},{"issue":"3\u20134","key":"pone.0240495.ref026","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1600-0684.1990.tb00442.x","article-title":"Inoculation of Macaca fascicularis with simian immunodeficiency virus, SIVmne immunologic, serologic, and pathologic changes","volume":"19","author":"L Kuller","year":"1990","journal-title":"J Med Primatol"},{"issue":"18","key":"pone.0240495.ref027","doi-asserted-by":"crossref","first-page":"7213","DOI":"10.1073\/pnas.86.18.7213","article-title":"Protection of macaques against simian AIDS by immunization with a recombinant vaccinia virus expressing the envelope glycoproteins of simian type D retrovirus","volume":"86","author":"SL Hu","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"pone.0240495.ref028","doi-asserted-by":"crossref","first-page":"5528","DOI":"10.4049\/jimmunol.157.12.5528","article-title":"Neutralizing and infection-enhancing antibody responses do not correlate with the differential pathogenicity of SIVmac239delta3 in adult and infant rhesus monkeys","volume":"157","author":"DC Montefiori","year":"1996","journal-title":"J Immunol"},{"issue":"4","key":"pone.0240495.ref029","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1182\/blood-2008-01-136473","article-title":"The C-type lectin surface receptor DCIR acts as a new attachment factor for HIV-1 in dendritic cells and contributes to trans- and cis-infection pathways","volume":"112","author":"AA Lambert","year":"2008","journal-title":"Blood"},{"issue":"2","key":"pone.0240495.ref030","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.4049\/jimmunol.182.2.1202","article-title":"Rapid degranulation of NK cells following activation by HIV-specific antibodies","volume":"182","author":"AW Chung","year":"2009","journal-title":"J Immunol"},{"issue":"3","key":"pone.0240495.ref031","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/00002030-200102160-00026","article-title":"Mucosal IgA in exposed, uninfected subjects: evidence for a role in protection against HIV infection","volume":"15","author":"R Kaul","year":"2001","journal-title":"AIDS"},{"issue":"6","key":"pone.0240495.ref032","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/QAD.0b013e3282f56b64","article-title":"HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers","volume":"22","author":"T Hirbod","year":"2008","journal-title":"AIDS"},{"issue":"4","key":"pone.0240495.ref033","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1699-0463.1995.tb01101.x","article-title":"IgA and mucosal defense","volume":"103","author":"ME Lamm","year":"1995","journal-title":"APMIS"},{"issue":"14","key":"pone.0240495.ref034","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"BF Haynes","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0240495.ref035","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1128\/JVI.02363-15","article-title":"Env-Specific IgA from Viremic HIV-Infected Subjects Compromises Antibody-Dependent Cellular Cytotoxicity","volume":"90","author":"MJ Ruiz","year":"2016","journal-title":"J Virol"},{"issue":"3","key":"pone.0240495.ref036","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/infdis\/160.3.385","article-title":"Antibodies to human immunodeficiency virus in vaginal secretions of heterosexual women","volume":"160","author":"L Belec","year":"1989","journal-title":"J Infect Dis"},{"issue":"9","key":"pone.0240495.ref037","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/00002030-200006160-00008","article-title":"Absence of specific mucosal antibody responses in HIV-exposed uninfected sex workers from the Gambia","volume":"14","author":"L Dorrell","year":"2000","journal-title":"AIDS"},{"issue":"18","key":"pone.0240495.ref038","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1089\/08892220152741388","article-title":"HIV-specific IgG in cervicovaginal secretions of exposed HIV-uninfected female sexual partners of HIV-infected men","volume":"17","author":"K Buchacz","year":"2001","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"3","key":"pone.0240495.ref039","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1128\/JVI.77.3.2165-2173.2003","article-title":"Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus","volume":"77","author":"JE Schmitz","year":"2003","journal-title":"J Virol"},{"issue":"19","key":"pone.0240495.ref040","doi-asserted-by":"crossref","first-page":"10447","DOI":"10.1128\/JVI.00049-13","article-title":"Neutralizing polyclonal IgG present during acute infection prevents rapid disease onset in simian-human immunodeficiency virus SHIVSF162P3-infected infant rhesus macaques","volume":"87","author":"JP Jaworski","year":"2013","journal-title":"J Virol"},{"issue":"1\u20133","key":"pone.0240495.ref041","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0165-2478(98)00151-5","article-title":"Rapid and slow progressors differ by a single MHC class I haplotype in a family of MHC-defined rhesus macaques infected with SIV","volume":"66","author":"DT Evans","year":"1999","journal-title":"Immunol Lett"},{"issue":"10","key":"pone.0240495.ref042","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nri2636","article-title":"Monkeying around with HIV vaccines: using rhesus macaques to define \u2019gatekeepers\u2019 for clinical trials","volume":"9","author":"DJ Shedlock","year":"2009","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"pone.0240495.ref043","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1001\/archinte.1997.00440330102012","article-title":"Postcoital vaginal bleeding as a risk factor for transmission of the human immunodeficiency virus in a heterosexual partner study in Brazil","volume":"157","author":"Rio de Janeiro Heterosexual Study Group","year":"1997","journal-title":"Arch Intern Med"},{"issue":"2","key":"pone.0240495.ref044","first-page":"78","article-title":"Nonoxynol-9 use, genital ulcers, and HIV infection in a cohort of sex workers","volume":"71","author":"SS Weir","year":"1995","journal-title":"Genitourin Med"},{"issue":"8","key":"pone.0240495.ref045","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/nm.2006","article-title":"Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition","volume":"15","author":"J Zhu","year":"2009","journal-title":"Nat Med"},{"issue":"12","key":"pone.0240495.ref046","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1093\/infdis\/jiu815","article-title":"Antiretroviral Pre-Exposure Prophylaxis Does Not Enhance Immune Responses to HIV in Exposed but Uninfected Persons","volume":"211","author":"L Pattacini","year":"2015","journal-title":"J Infect Dis"},{"issue":"3","key":"pone.0240495.ref047","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/QAD.0b013e3282f3ca57","article-title":"Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope","volume":"22","author":"SW Barnett","year":"2008","journal-title":"AIDS"},{"issue":"4","key":"pone.0240495.ref048","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/QAI.0000000000000642","article-title":"Repeated Vaginal SHIV Challenges in Macaques Receiving Oral or Topical Preexposure Prophylaxis Induce Virus-Specific T-Cell Responses","volume":"69","author":"TS Tsegaye","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"pone.0240495.ref049","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1006\/clim.2001.5141","article-title":"Systemic and mucosal immune responses in mice after rectal and vaginal immunization with HIV-DNA vaccine","volume":"102","author":"K Hamajima","year":"2002","journal-title":"Clin Immunol"},{"issue":"8","key":"pone.0240495.ref050","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1089\/0889222041725253","article-title":"An SHIV DNA\/MVA rectal vaccination in macaques provides systemic and mucosal virus-specific responses and protection against AIDS","volume":"20","author":"SW Wang","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"1\u20132","key":"pone.0240495.ref051","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0022-1759(98)00145-8","article-title":"Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization","volume":"220","author":"Z Durrani","year":"1998","journal-title":"J Immunol Methods"},{"issue":"40","key":"pone.0240495.ref052","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.1016\/j.vaccine.2008.03.066","article-title":"Intranasal immunization of young mice with a multigene HIV-1 vaccine in combination with the N3 adjuvant induces mucosal and systemic immune responses","volume":"26","author":"A Brave","year":"2008","journal-title":"Vaccine"},{"issue":"4","key":"pone.0240495.ref053","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.intimp.2009.01.012","article-title":"Intranasal administration of peptide antigens of HIV with mucosal adjuvant CpG ODN coentrapped in microparticles enhances the mucosal and systemic immune responses","volume":"9","author":"PB Pun","year":"2009","journal-title":"Int Immunopharmacol"},{"key":"pone.0240495.ref054","doi-asserted-by":"crossref","first-page":"36658","DOI":"10.1038\/srep36658","article-title":"Mucosal vaccination with a live recombinant rhinovirus followed by intradermal DNA administration elicits potent and protective HIV-specific immune responses","volume":"6","author":"K Tomusange","year":"2016","journal-title":"Sci Rep"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0240495","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T20:30:10Z","timestamp":1698957010000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0240495"}},"subtitle":[],"editor":[{"given":"Pierre","family":"Roques","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,4,29]]},"references-count":54,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0240495","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.09.30.320820","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,29]]}}}